Global & USA Cancer Immunotherapy Market Analysis 2015 - Forecasts to 2020

DUBLIN, Oct. 09 2015 /PRNewswire/ --

Research and Markets(http://www.researchandmarkets.com/research/lgcqzq/global_and_usa) has announced the addition of the "Global & USA Cancer Immunotherapy Market Analysis to 2020" report to their offering.

Global & USA Cancer Immunotherapy Market Analysis to 2020: Antibody Drug Conjugates (ADCs), Bispecific Monoclonal Antibodies, Cancer Vaccines, Cytokines, Interferons, Chimeric Antigen Receptor (CAR) T-Cell Therapy, PD-1/PD-L1 inhibitors, Dendritic Cells, Checkpoint Inhibitors, Adopted Cell Therapy (ACT) & IDO Inhibitors

This latest cutting-edge analysis of the Global & USA Cancer Immunotherapy Market Analysis to 2020 reveals that the cancer immunotherapy space will be a significant revenue generator (excess of $80 billion) for the biopharmaceutical industry by 2020. The market has been supported by the approval of Bristol-Myers' Yervoy drug for melanoma (2011) and Dendreon's Provenge (2010) for prostate cancer. Over the next decade, immunotherapies will be the backbone of cancer treatments in 60% of cancer types. It is forecast that by 2020, Avastin, Nivolumab, Revlimid, Rituxan and Xtandi will be the top five cancer drugs. A single drug, Bristol-Myers Squibb's Yervoy, for example has earned revenues of about $960 million in 2013 and it is expected to have a market value of $1,775.2 million in 2020. Industry Experts have predicted that Keytruda and Opdivo will generate sales revenues of $2.9 billion and $4.3 billion respectively in 2019.

An unmet need in the cancer therapy market has paved the way for immunotherapies and has increased patient survival rates significantly indicates Dr Deirdre Kelly, Owner of KellySciPub.com, Today significant therapeutic interest into ADC's, checkpoint inhibitors, cancer vaccines and anti-PD-1/PD-L1 agents are taking the market by storm, and we forecast vertical growth in this area within the next decade'. Therefore, it is no wonder that in 2013, most science journals hailed cancer immunotherapy as the breakthrough treatment of the year.

The interest on ADCs can be seen with the recent approvals of Adcetris (brentuximab vedotin) and Kadcyla (ado-trastuzumab emtansine). Currently, More than 15 companies are developing 30 different ADCs targeting both hematologic malignancies and solid tumors. ADCs represent a novel class of therapeutic agents, gaining increasing attention from both large and small pharmaceutical companies. As the ADCs carry a chemotherapy drug, they are believed to be more efficient and effective in the treatment of a disease. Due to shrinking pipelines and increasing pressure from patent expirations, big pharmaco' recognized the vaccine market as a potential resource for investors. Cancer vaccines have been found to earn a higher profit than the generic drugs, owing to the nature of the disease and the urgency in the demand for these vaccines.

Immunotherapy is a proven powerful tool, either as a monotherapy or as a combination therapy with chemotherapy or radiation. For patients with metastatic skin cancer or kidney cancer, immunotherapy has been found to be more effective than the conventional options, with the possibility of even a complete cure. Today, cancer immunotherapy drugs have captured nearly 50% of the overall oncology drugs market, generating about $41.0 billion in 2014 alone. This report describes the evolution of such a huge market in 11 chapters supported by 114 tables and 41 figures, over 256 pages.

Key Topics Covered:

1.0 Executive Summary

2.0 Cancer Immunotherapy: An Overview

3.0 Current Status of Cancer Immunotherapy: An Overview

4.0 Challenges in Cancer Medicine Research: An Overview

6.0 Available Immunotherapies for Cancer by Disease Type: An Overview

7.0 Cancer Incidence and Mortality: An Overview

8.0 Market Analysis

9.0 Market for Cancer Immunotherapy

10.0 Company Profiles

- Ablynx NV
- Activartis Biotech GmbH
- Advaxis Inc.
- Aduro BioTech Inc.
- Agenus Inc.
- AlphaVax Inc.
- A. Menarini
- Amgen Inc.
- Antigen Express Inc.
- Argos Therapeutics Inc.
- Bavarian Nordic A/S
- Bellicum Pharmaceuticals Inc.
- Biogen Idec Inc.x
- Biovest International Inc.
- Bristol-Myers Squibb Co.
- Cellectis
- Cellerant Therapeutics Inc.
- Celldex Therapeutics
- CEL-SCI Corp.
- CureTech Ltd
- Delta-Vir GmbH
- Dendreon Corp.
- DenDrit Biotech USA
- DNAtrix Inc.
- Eli Lilly and Co.
- EMD Serono Inc.
- Etubics Corp.
- Galena Biopharma Inc.
- Genentech Inc.
- Genmab AS
- GlaxoSmithKline
- Gliknik Inc.
- GlobeImmune Inc.
- Heat Biologics Inc.
- Immatics Biotechnologies GmbH
- ImmunoCellular Therapeutics Ltd.
- Immunocore Ltd
- ImmunoFrontier Inc.
- ImmunoGen Inc.
- Immunomedics Inc.
- Immunotope Inc.
- Immunovaccine Inc.
- Inovio Pharmaceuticals Inc.
- Janssen Biotech Inc.
- Juno Therapeutics Inc.
- Kite Pharma Inc.
- MabVax Therapeutics Holdings Inc.
- MedImmune LLC
- Merck & Co., Inc.
- Merrimack Pharmaceuticals Inc.
- Morphotek Inc.
- NewLink Genetics Corp.
- Northwest Biotherapeutics Inc.
- NovaRx Corp.
- OncoPep Inc.
- Oncothyreon Inc.
- OSE Pharma SA
- Oxford BioTherapeutics Ltd.
- Pique Therapeutics
- Polynoma LLC
- Prima BioMed Ltd.
- Progenics Pharmaceuticals Inc.
- Regen Biopharma Inc.
- Roche Holdings Inc.
- Seattle Genetics Inc.
- Sorrento Therapeutics Inc.
- Spectrum Pharmaceuticals Inc.
- Synthon Pharmaceuticals Inc.
- TapImmune Inc.
- ThioLogics Ltd.
- Transgene SA
- TVAX Biomedical Inc.
- Vaccinogen Inc.
- Viventia Biotechnologies Inc.
- Wilex AG

For more information visit http://www.researchandmarkets.com/research/lgcqzq/global_and_usa

Media Contact: Laura Wood , +353-1-481-1716, [email protected]

SOURCE Research and Markets

Related Links

http://www.researchandmarkets.com